Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer by Graziano, Francesco et al.
BMC Cancer (2001) 1:9 http://www.biomedcentral.com/1471-2407/1/9
BMC Cancer (2001) 1:9 Research article
Potential role and chronology of abnormal expression of the 
Deleted in Colon Cancer (DCC) and the p53 proteins in the 
development of gastric cancer
Francesco Graziano*1, Stefano Cascinu2, Maria Pia Staccioli3, 
Vincenzo Catalano4, Maria Cristina Rossi4, Anna Maria Baldelli4, 
Paolo Giordani4, Pietro Muretto3 and Giuseppina Catalano4
Address:  1Medical Oncology Unit, Hospital of Urbino, Italy, 2Division of Medical Oncology, Hospital of Parma, Italy, 3Department of 
Histopathology, Hospital of Pesaro, Italy and 4Medical Oncology, Hospital of Pesaro, Italy
E-mail: Francesco Graziano* - frada@tin.it; Stefano Cascinu - cascinu@yahoo.com; Maria Pia Staccioli - oncops@yahoo.com; 
Vincenzo Catalano - oncops@yahoo.com; Maria Cristina Rossi - oncops@yahoo.com; Anna Maria Baldelli - oncops@yahoo.com; 
Paolo Giordani - oncops@yahoo.com; Pietro Muretto - oncops@yahoo.com; Giuseppina Catalano - oncops@yahoo.com
*Corresponding author
Abstract
Background:  Loss of activity of tumor suppressor genes is considered a fundamental step in a
genetic model of carcinogenesis. Altered expression of the p53 and the Deleted in Colon Cancer
(DCC) proteins has been described in gastric cancer and this event may have a role in the
development of the disease. According to this hypothesis, we investigated the p53 and the DCC
proteins expression in different stages of gastric carcinomas.
Methods:  An immunohistochemical analysis for detection of p53 and DCC proteins expression
was performed in tumor tissue samples of patients with UICC stage I and II gastric cancer. For the
purpose of the analysis, the staining results were related to the pathologic data and compared
between stage categories.
Results:  Ninety-four cases of gastric cancer were analyzed. Disease stage categories were pT1N0
in 23 cases, pT2N0 in 20 cases, pT3N0 in 20 cases and pT1-3 with nodal involvment in 31 cases.
Stage pT1-2N0 tumors maintained a positive DCC expression while it was abolished in pT3N0
tumors (p <.001). A significant higher proportion of patients with N2 nodal involvement showed
DCC negative tumors. In muscular-invading tumors (pT2-3N0) the majority of cases showed p53
overexpression, whereas a significantly higher proportion of cases confined into the mucosa
(pT1N0) showed p53 negative tumors. Also, a higher frequency of p53 overexpression was
detected in cases with N1 and N2 metastatic lymphnodal involvement.
Conclusions:   Altered expression of both DCC and p53 proteins is detectable in gastric
carcinomas. It seems that loss of wild-type p53 gene function and consequent p53 overexpression
may be involved in early stages of tumor progression while DCC abnormalities are a late event.
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Introduction
Experimental data support the hypothesis that tumors
may originate from the accumulation of genetic defects.
In a model of multi-step carcinogenesis, mutations of the
Deleted in Colon Cancer (DCC) and the p53 tumor sup-
pressor genes with functional abnormalities of the pro-
teins they encode may be involved in the development of
a variety of tumors [1].
In gastric cancer, p53 abnormalities have been observed
in 5% to 70% of cases [2]. The most common are mis-
sense mutations which usually prolong the half-life of
the p53 abnormal protein causing its nuclear accumula-
tion and the detection by immunohistochemistry. Exper-
imental data suggest a chronology for the loss of p53
function and similarities with the carcinogenetic model
of colorectal cancer [3,4].
The DCC gene encodes for a membrane-bound protein
belonging to the immunoglobulin superfamily which can
be detected by immunohistochemistry with a commer-
cial monoclonal antibody [5]. Abnormalities of the DCC
tumor suppressor gene and abolished DCC function may
be critically involved in the development of gastric can-
cer [6–11]. Recent studies found that the DCC gene is in-
volved in the regulation of axonal development as a
component of the Netrin-1 receptor, and some investiga-
tions failed to demonstrate the role of DCC in the car-
cinogenetic process [12]. More recently, the DCC gene
product was found to induce apoptosis activating cas-
pase-3 and high levels of DCC expression were associat-
ed to an effective apoptotic process [13,14]. Thus, DCC
may function as tumor suppressor gene which controls
programmed cell death [13].
In the malignant progression of this disease, early inves-
tigations have suggested that the DCC gene damage may
occur after the loss of heterozygosity on the p53 gene lo-
cation [6]. However, the consecution and timing of these
events is still unclear [7–10], and the role and the chro-
nology of p53 and DCC alterations in the genesis and
progression of gastric cancer are still under investigation
[11].
On these bases, we have performed a combined analysis
of p53 and DCC proteins expression in consecutive cases
of gastric carcinoma. Patients with UICC stages I and II
were considered eligible for the analysis, staining results
were correlated with the depth of tumor invasion into the
gastric wall and nodal involvement.
Materials and Methods
The study population consisted of patients referred to
our Insitutions after radical surgery for stage pT1-
3N0M0 and pT1-3N1-2M0 gastric cancer. The analysis
was carried out on tumor tissue from the primary tumors
and all the cases were reviewed independently by two pa-
thologists.
Paraffin-embedded tumor blocks were analyzed by im-
munohistochemistry for DCC and p53 proteins expres-
sion using a standard avidin-biotynilated peroxidase
complex (ABC) staining method [15]. Sections (4 m
thick) were deparaffinised in xylene, rehydratated in a
graded ethanol series and incubated in 3% hydrogen-
peroxide for 20 min. Specimens were placed in a plastic
Coplin jar containing citric buffer and heated 4 ×  2.5 min
in a microwave processor at 95°C. After the microwave
processing, sections were left in the Coplin jar at room
temperature for 30 min. Specimens were covered with
normal goat serum for 15 min to reduce nonspecific
staining and incubated at room temperature for 1 hour
with a murine monoclonal antibody for p53 (clone
DAKO D07, Copenhagen, Denmark; dilution 1:75) and a
rabbit polyclonal antibody for DCC (clone G97-449,
Pharmingen, San Diego, CA at 1:500 dilution). The sec-
tions were washed with Tris-buffered saline, incubated
with a 1:100 dilution of biotinylated goat anti-mouse im-
munoglobulin G at room temperature for 30 min, and
then covered with a 1:100 dilution of streptavidin-biotin-
peroxidase complex at room temperature for 30 min.
The antibody was localized with 3,3'-diaminobenzidine
tetrahydrochloride (DAB). Tissue sections were counter-
stained with light haematoxylin, dehydrated with etha-
nol and mounted under a coverslip.
In each case, the entire section was systemically exam-
ined on high-power fields (x400) for DCC and p53 im-
munoreactivity. The level of immunoreactivity was
expressed as the percentage of stained cancer cells (0%
to 100%); the 25% and the 5% cut-off values were adopt-
ed for DCC and p53 respectively [16,17].
Statistical analysis was performed to correlate the results
of DCC and p53 staining to the pathologic features of tu-
mors. In a preliminary step, diffuse and intestinal histo-
types were analyzed for DCC and p53 expression; both
subtypes were included in the final analysis in the case of
no significant distribution of positive and negative cases
between the two histologies.
According to the cut-off values, the results of DCC and
p53 analyses were used as dichotomized (categorical)
variable. Contingency tables were analyzed by the Fish-
er's exact test or the Chi-square test as appropriate. All
the values were two-sided and statistical significance was
defined as p < .05.BMC Cancer (2001) 1:9 http://www.biomedcentral.com/1471-2407/1/9
Results
The analysis was performed in tumors of 94 out of 100 el-
igible patients who underwent radical surgery for gastric
cancer. Six cases (5%) were exluded due to unassessable
archival tumor tissue. Stage disease was: pT1-3N0 in 63
patients, pT1-3N1 in 15 patients and pT1-3N2 in 16 pa-
tients. Clinico-pathologic features of the 94 patients are
reported in Table 1.
DCC analysis showed a clear dichotomized distribution
of positive and negative cases; negative cases showed 0%
to <5% stained cells, while positive cases showed > 75%
stained cells. Thus, the 25% cut-off value was unneces-
sary and we observed an "all or nothing"-like phenome-
non as reported by Shibata et al [16]. The DCC wild-type
protein was detected in 58 cases (62%) and it was absent
in 36 cases (38%).
In the present series, 24 cases were categorized p53 neg-
ative (26%); 18 cases showed no nuclear p53 expression
and 24 cases less or equal 5% of stained cell nuclei. The
p53 overexpression was found in 70 cases (74%) and the
mean percentage of p53 overexpressing cells was 45%.
Both diffuse and intestinal subtypes showed abolished
DCC expression and/or p53 overexpression. No statisti-
cally significant distribution of DCC/p53 postive and
negative cases was observed in the subset analysis of dif-
fuse and intestinal subtypes (data not shown). The re-
sults of the DCC analysis in tumors of 63 patients with
node-negative disease are summarized in Table 2. The
majority of pT1N0 and pT2N0 cases maintained positive
DCC protein expression while it was significantly re-
duced in pT3N0 cases (p = .001). A significantly higher
number of node-negative tumors maintained DCC ex-
pression (p = .007), while abolished DCC expression was
significantly related to a more advanced lymphnodal in-
volvement; in fact, the majority of N2 cases showed DCC
negative tumors (p = .001) (Table 3).
In Table 4 are reported the results of the p53 analysis in
the 63 patients with node-negative tumors. In muscular-
invading tumors (pT2-3N0) the majority of cases
showed p53 overexpression, whereas a significantly
higher proportion of cases confined into the mucosa
(pT1N0) showed p53 negative tumors (p = .001). Also, a
higher frequency of p53 overexpression was detected in
cases with metastatic lymphnodal involvement (p = .003
without major differences between N1 and N2 cases (Ta-
ble 5).
Table 1: Characteristics of the 94 patients included in the study
Age (yrs)
Median 62
Range 48–81
Sex
Male 51 (54%)
Female 43 (46%)
Tumor site
Antrum 27 (28%)
Body 30 (32%)
Cardias 37 (40%)
Grading
Well diff. 27 (28%)
Moderately diff. 32 (34%)
Poorly diff. 35 (38%)
Subtype
Intestinal 42 (44%)
Diffuse 52 (56%)
Stage
pT1N0 23 (25%)
pT2N0 20 (22%)
pT3N0 20 (22%)
pT1-3N1 15 (15%)
pT1-3N2 16 (16%)
p53
positive 70 (74%)
negative 24 (26%)
DCC
positive 58 (62%)
negative 36 (38%)
Table 2: Analysis of DCC expression in the 63 node-negative 
cases
DCC positive DCC negative
pT1N0 22 (35%) 1 (1.5%)
pT2N0 17 (27%) 3 (5%)
pT3N0 6 (9.5%) 14 (22%)
Table 3: Analysis of DCC expression in node-negative and node-
positve cases and in the 31 cases with lymphnodal involvment (N1 
vs N2)
DCC positive DCC negative
Node negative 45 (48%) 18 (19%)
Node positive 13 (14%) 18 (19%)
pT1-3N1 10 (32%) 5 (16%)
pT1-3N2 3 (10%) 13 (42%)BMC Cancer (2001) 1:9 http://www.biomedcentral.com/1471-2407/1/9
Discussion
In 1992, Uchino et al [6] first reported experimental data
supporting the role of DCC abnormalities in the patho-
genesis of gastric cancer. Interestingly, they found that
loss of heterozygosity (LOH) of the DCC gene occurred
irrespective of the stage of disease. Fang et al. [7] found
that LOH of the DCC gene was a late phenomenon and
associated with the malignant progression of gastric can-
cer. Wu et al [8] described LOH of the DCC gene in ad-
vanced intestinal gastric cancer and infrequently in early
or advanced diffuse histotype. Also, the analysis of DCC
mRNA expression levels showed correlation with the
clinicopathologic features of gastric carcinomas which
had significantly lower expression than normal tissues
[9,10]. Available data are consistent with a relationship
between DCC impaired function and the development of
gastric cancer, however, the chronology of this event is
unclear yet [11].
In the present study, the majority of pT1-2 tumors main-
tained the DCC protein expression which was signifi-
cantly reduced in T3 tumors, or in cases with
lymphnodal involvement. These data support the hy-
pothesis that loss of wild-type DCC function is a late
event in the progression of gastric cancer, and the gene
protein product is reduced in more advanced stages of
the disease. Actually, Wu et al [8] found infrequent LOH
of the DCC gene in the advanced diffuse histotype; this
observation was not confirmed by Fang et al [7] who did
not find any correlation between LOH of the DCC gene
and histologic subtypes of gastric carcinomas.
Gastric cancer and colorectal cancer may share a genetic
model of carcinogenesis [3–7], and alterations of the p53
tumor suppressor genes may happpen at some point of
the malignant progression preceding or following the
DCC damage. In colorectal cancer, the Vogelstein's mod-
el of multi-step carcinogenesis suggests that the DCC
gene damage precedes abnormalities of the p53 gene [2],
however, both DCC and p53 aberrations seem to be late
events in the development of colorectal cancer [18].
In gastric cancer, available data suggest that a p53 im-
paired function represent an early event in the carcino-
genetic process [19]. Also, p53 accumulation positively
correlated with increasing tumor stage, size and lymph-
nodal involvment [19–22]. Oiwa et al [23] found that p53
gene abnormalities and protein overexpression may play
an important role in cancer expansion, providing tumors
with a potential of vertical growth into the gastric wall.
Wu et al [8] and Kataoka et al [11] attempted a combined
analysis of the p53 and the DCC status in gastric cancer.
Their findings on the timing of genetic damage are dis-
cordant, notably, in the largest series by Wu et al [8], p53
abnormalities resulted an early event and LOH of the
DCC gene a late event.
In the present series, the phenomenon of p53 overex-
pression correlated with the tumor progression from the
intra-mucosal stage to the muscular-invading stage,
while abolished DCC function was detected in tumors
deeply infiltrating the gastric wall or with lymphnodal
involvement. These findings support the hypothesis that
abnormalities of both tumor suppressor genes may be in-
volved in the pathogensis of gastric cancer, and the p53
damage may precede an abolished DCC function. On the
whole, these data suggest a different chronology for the
accumulation of p53 and DCC genetic defects in compar-
ison with colorectal cancer.
The present investigation has strenghts and limitations.
Our findings may contribute to a better knowledge of ge-
netic events underlying the development of gastric can-
cer, but given the retrospective nature of the study,
results need confirmation in further series. Also, future
investigations should consider the possibility of germline
mutations of these tumor suppressor genes, and conse-
quently, the identification of families with affected mem-
bers and healthy carriers who may be at risk for gastric
cancer development.
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Table 4: Analysis of p53 expression in the 63 node-negative cases
p53 positive p53 negative
pT1N0 8 (12%) 15 (24%)
pT2N0 17 (27%) 3 (5%)
pT3N0 17 (27%) 3 (5%)
Table 5: Analysis of p53 expression in node-negative and node-
positve cases and in the 31 cases with lymphnodal involvment (N1 
vs N2)
p53 positive p53 negative
Node negative 42 (45%) 21 (22%)
Node positive 28 (30%) 3 (3%)
pT1-3N1 13 (42%) 2 (6%)
pT1-3N2 15 (48%) 1 (3%)BMC Cancer (2001) 1:9 http://www.biomedcentral.com/1471-2407/1/9
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